19 Results
Summary of January 2023 Advisory Council Meeting
Funding News Edition: February 15, 2023
NIAID Acting Director Dr. Hugh Auchincloss provided updates on HIV/AIDS, malaria, Ebola, a promising Marburg vaccine, universal flu vaccine efforts, non-viral asthma attacks, monoclonal antibodies to target Epstein-Barr virus, and human antibody response to vaccinations.
A Summary of Outcomes from Our September Advisory Council Meeting
Funding News Edition: October 4, 2023
NIAID Acting Director Dr. Hugh Auchincloss provided remarks on the Institute’s administrative, budget, and scientific news. He was followed by guest speaker Dr. Ted Pierson, Director of NIAID’s Vaccine Research Center, who discussed recent scientific advances and ongoing research priorities.

Highlights from June’s Advisory Council Meeting
Funding News Edition: June 21, 2023
NIAID Acting Director Dr. Hugh Auchincloss discussed administrative, budget, and legislative updates, as well as recent scientific findings. Then Dr. Steven Holland, Director of NIAID’s Division of Intramural Research, described key research accomplishments at our intramural laboratories.

Reviewing NIAID’s Application and Award Counts for FY 2022
Funding News Edition: February 15, 2023
We share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year (FY) as well as how many awards NIAID made in turn.

New Leaders Take Center Stage at Advisory Council Meeting in January
Funding News Edition: February 21, 2024
This was the first meeting at which NIAID Director Dr. Jeanne Marrazzo shared remarks before NIAID's Advisory Council. It was also the first time that guest speaker Dr. Monica Bertagnolli, NIH Director, addressed our Council.

Administrative Supplement Supports Research Testing on Gender Measurement
Funding News Edition: February 15, 2023
The health conditions of interest to NIAID impact the health of sexual minority and majority populations, and the Institute endorses meaningful sexual orientation and gender identity measurement in research, clinical care, and administrative settings.
Long COVID and the RECOVER-TLC Initiative
Funding News Edition: November 6, 2024
Long COVID’s broad and varied effects on diverse populations demand new clinical approaches and fewer restrictions to inclusion and access to achieve breakthrough results.

A Rule Change for Preliminary Data as Post-Submission Materials
Funding News Edition: April 19, 2023
NIH will allow applicants to submit preliminary data as post-submission materials for new applications (Type 1) if the notice of funding opportunity uses the R01, R03, or R21 activity codes and allows preliminary data.
Distribution of Applications by Career Stage Held Steady Through the Pandemic
Funding News Edition: August 16, 2023
The most recent analysis found a continual increase in the proportion of applications designating either female or underrepresented minority early-stage investigators both before and after the pandemic.
December’s ACD Meeting—Featuring Bill Gates and Dr. Anthony Fauci
Funding News Edition: February 1, 2023
NIH’s Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.
NIAID Wants Your Feedback on Strategic Plan to Accelerate Tuberculosis Research
Funding News Edition: July 6, 2023
Our revised Strategic Plan is structured around five strategic priorities that capitalize on recent advances in the field; each critical to the development and evaluation of knowledge and tools needed to end tuberculosis globally.
Publicize Your Research Findings Through NIAID
Funding News Edition: July 6, 2023
When you’re ready to publicize your scientific discoveries, let NIAID help spread the word. Through a variety of communication vehicles, our News and Science Writing Branch highlights the work of NIAID-funded researchers.
Provide Feedback to Help NIH Evaluate Postdoctoral Research Training
Funding News Edition: March 1, 2023
Share your thoughts on the roles and responsibilities of academic postdocs, including challenges in recruitment, retention, and quality of life of postdoctoral trainees.
Four Research Areas Comprise NIAID’s 2023 Omnibus Contract Solicitation
Funding News Edition: February 1, 2023
Successful offerors will help advance the research and development of promising candidate vaccines, therapeutics, and diagnostics for biodefense, emerging infectious diseases, and pandemic preparedness.
News Briefs and Worth Repeating
Funding News Edition: October 16, 2024
With Gratitude to Dr. Hugh Auchincloss, and a Welcome to Dr. Sarah Read; Newcomer to NIH Funding? Attend the NIH Grants Process Primer Webinar; OLAW Annual Reports Are Due on December 1; Loan Repayment Program Application Deadline Is November 21
Take Note of Reissued Investigator-Initiated Clinical Trial NOFOs
Funding News Edition: February 7, 2024
The NIAID Clinical Trial Implementation Cooperative Agreement notice of funding opportunity (NOFO) is designed for high-risk trials. The NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement NOFO allows small business concerns to proposed investigator-initiated clinical trials.
Examining NIAID’s R01 and R21 Application and Award Counts for FY 2023
Funding News Edition: March 6, 2024
We share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year as well as the number of grants NIAID awarded. To add context, we present the data alongside the same figures for the preceding 4 years.

Tabulating NIAID’s R01 and R21 Application and Award Counts for FY 2024
Funding News Edition: December 18, 2024
Each year, we share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year as well as the number of grants NIAID awarded.

Happenings from the September Meeting of NIAID’s Advisory Council
Funding News Edition: October 2, 2024
NIAID Director Dr. Jeanne Marrazzo shared remarks before NIAID's Advisory Council, as did Dr. Ted Piersen, Director of NIAID’s Vaccine Research Center.

Contact Us
Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.